
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics Inc. is making significant strides in its clinical-stage development of therapies for solid tumors, particularly focusing on female, hormone-dependent cancers, with the CTIM-76 program showing promising early clinical activity and a favorable safety profile. The company's robust pipeline, combined with a strong financial position that extends funding into 2027, provides a solid foundation for ongoing clinical evaluations and potential partnerships. Positive early dose escalation data and first-in-human signals suggest the potential for de-risking the development programs, indicating multiple value catalysts that could drive investor interest in the near term.
Bears say
Context Therapeutics Inc. reported a significant decrease in research and development expenses, dropping to $8.7 million from $16.8 million in Q3 2024, reflecting a lack of prior-year in-process charges tied to specific projects. Despite a reduction in net loss from $17.5 million to $9.7 million for Q3 2025, the company faces multiple risks that could adversely impact its financial stability, including potential safety concerns in clinical programs, competitive market pressures, and regulatory hurdles. Additionally, Context may require approximately $250 million in additional financing through 2041, with projections indicating a cash runway only through 2027, raising concerns about its longer-term viability and operation sustainability.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares